300142:SZSEWalvax Biotechnology Co., Ltd. Class A Analysis

Walvax Biotechnology is trading at CNY13.98, comfortably above its 20‑day (13.27), 50‑day (12.64) and 200‑day (12.29) moving averages, with a bullish MACD and a neutral‑to‑bullish RSI of 55.9. Volume is rising and the price sits near the upper end of its 52‑week range, indicating strong short‑term momentum.
However, valuation metrics tell a different story: a trailing PE of 78× versus an industry average of 27×, a forward PE still above 30×, and a DCF‑derived fair value of only CNY3.35, implying a ~43% downside. The company’s ROE is just 2.7%, free cash flow is negative, and debt‑to‑equity exceeds 17×, raising concerns about financial sustainability. The modest 0.29% dividend is technically sustainable but offers little income.
Risk factors include very high 30‑day volatility (~65%), medium regulatory exposure typical for vaccine makers, and geographic concentration in China, though market‑beta is low at 0.31 and liquidity is strong. Overall, the technical upside is outweighed by fundamental overvaluation and balance‑sheet strain.